![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
|Videos|December 14, 2022
Interview with Syngene at CPHI in Frankfurt, Germany
Author(s)Syngene
KEY LEARNING OBJECTIVES
- Syngene is an end-to-end CRO/CDMO which offers standalone as well as integrated services for small molecules and biologics
- We not only have capabilities but also capacity to fulfil commercial manufacturing requirements
- We can be a innovation partner for niche areas as well as small biotech/pharma companies
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
Everything to Know About Pharmaceutical Tariffs in 2025
2
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
3
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
4
Challenges for the Global Manufacturing of Vaccines
5
